The First Controlled Clinical Trial For A CRISPR Enhanced Bacteriophage Therapy
August 24, 2020
In a recent article published in Clinical Leader, Ed Miseta, Chief Editor highlights Medpace’s partnership with Locus Biosciences and their development of crPhage™, a bacteriophage that have been engineered to deliver the CRISPR-Cas3 constructs into the target bacteria.
Read More